Sixth Wave’s Dr Jon Gluckman on the First Polymer for Detection of SARS-CoV-2

In a recent InvestorIntel interview, Peter Clausi speaks with Dr. Jon Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF) about their recent news: First Polymer for Detection of SARS-CoV-2

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Gluckman went on to say that Sixth Wave is working in collaboration with the University of Alberta to develop COVID-specific Imprinted Polymers that can detect viruses even after they have mutated. Sixth Wave is currently developing this technology specifically for the COVID-19 virus but can potentially be used to detect any virus. He highlighted that the technology is low-cost, easy to use, and scalable.

Speaking on the potential implementations of their technology Dr. Gluckman said that the technology can be used in handheld devices, wearables, and airborne detection tools. Sixth Wave is currently designing, Smart Mask™ that will use the Imprinted Polymers to detect the COVID-19 virus in the user’s breath.

To watch the full interview, click here

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPs) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The Company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

To learn more about Sixth Wave Innovations Inc., click here

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.




MiCOVID Cam thermal temperature screening helps schools and businesses reopen safely

Direct Communication Solutions leads the way in smart, unmanned screening tech

COVID-19 continues to spread globally, now at a staggering 22,306,538 confirmed cases and 784,353 deaths. Companies developing technologies to quickly and accurately screen for possible COVID-19 cases in the community are seeing their stock prices surge. There is one small company that has developed a new AI thermal detector with cutting edge facial recognition which is currently under the radar of investors.

That company is Direct Communication Solutions Inc. (CSE: DCSI | OTCQB: DCSX) (“DCS”), an Internet of Things (IoTs) solutions company. IoTs solutions provide better ways for businesses to collect and assess business-critical data from all types of assets and devices using their hardware, software applications and scalable cloud services.

In late July 2020, DCS announced their latest product, a new AI thermal detector with cutting edge facial recognition and body temperature detection, known as MiCOVID Cam. DCS say that by “utilizing the latest AI chipset technology, MiCOVID Cam offers immediate body temperature detection, the longest sensor range, and the highest level of accuracy available in the market today.” The MiCOVID Cam is fully integrated into the DCS Web Services offering. DCS has also developed a 7 in 1 sensor which is significantly cheaper and offers seven sensors packaged together compared to competitors just one sensor.

Direct Communication Solutions new MiCOVID cam is designed to automatically screen for COVID-19 in businesses and schools

Source

A unique feature to DCS’s MiCOVID Cam is it offers employers a web-based solution without the need for operators by using its advanced AI. This makes it a cost-effective solution for screening the temperatures of visitors, employees or students. MiCOVID Cam can even automatically detect if employees or customers are wearing a mask or not. Employers can save the costs of manual screening by automating the whole process. In some cases the US CARES Act has paid for screening devices, recognizing the urgent need for better screening.

Fast mass screening has been a challenge. The MiCOVID Cam solution is capable of automatically screening up to 2,400 persons per hour, making it ideal for large businesses, organizations and schools.

The MiCOVID Cam in use at a Poland School District automatically screening students, staff, and teachers

Source: You can watch the video here.

David Scowby, COO of DCS explains that the “MiCovid Cam is another milestone achievement for DCS and fits into our strategy of providing our IoT technologies and Web Services to our partners developing next generation software applications… It is a unique time where our economy is needing the support to reopen, and offering MiCovid Cam is a way for businesses to reopen with advanced safety solutions.”

These are certainly unique times. COVID-19 continues to spread through the community and screening measures such as the DCS MiCOVID Cam is a much needed smart product to help identify and minimize the spread of COVID-19, or other infectious diseases with a thermal imprint. The automatic screening without the need of staff is a significant and natural advantage for DCS, as they offer a suite of web-connected IoTs solutions for their customers.

DCS’s technologies is already established in California and has a growing number of partners including Sprint, Cellcom, Bluegrass Cellular, Bell, CCA, Inland Cellular, US Cellular, SkyEye GPS, Verizon, and Telus. Strategic partners include Queclink, Cal/Amp. Telit, ATrack, and GoldenM.

Closing remarks

I think DCS’s MiCOVID Cam is a significant and timely addition to the company’s sensor technologies and can be an important tool in the fight to slow the spread of COVID-19, so a win-win for all. Added to MiCOVID Cam, DCS has three other key IoTS products – MiFleet (GPS tracking), MiSensors (remote monitoring system), and Brewsee (a beer life cycle monitor & control system). All of this is part of what is a rapidly growing IoTs global market forecast to reach US$1.1 trillion by 2023 and with a forecast 21.5 billion connected devices worldwide by 2025.

Direct Communication Solutions Inc. is currently trading on a market cap of just C$14.7m despite last year having C$16m in revenue, essentially at a valuation of below 1x revenue, which is generally considered very cheap. This is before factoring in any potential future revenues from their new MiCOVID Cam solution. Investors may not want to wait too long on this one as cutting-edge technologies tend to move quickly once discovered by industry and investors.




Dr Gluckman on the rapid-detection benefits of Sixth Wave’s virus test kits

“You can think about our polymer almost like an antibody inside a body,” says Dr. Jonathan Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF), in an interview with InvestorIntel’s Tracy Weslosky. “A virus has a size and shape and we create an imprint in our polymer for that exact virus. Then we will detect that directly based on our chemistry,” he continued. “We are working to integrate this into masks and breathalyzers and then we can just utilize the breath, as we all know that’s the main transmission method. If you think about putting a mask on, not only will that mask provide protection, it can also, right there, be the test for COVID-19.”

Dr. Gluckman explained that Sixth Wave’s COVID-19 detection technology is currently under development but the company has successfully launched and commercialized other products with similar properties. The company has received a grant from the Canadian government to work with York University and the CTRI (Centre Technologique des Résidus Industriels) to use its virus detection technology to detect COVID-19 virus in wastewater supplies and in air handling systems.

Highlighting the advantages of Sixth Wave’s COVID-19 test over other tests, Dr. Gluckman also said that the test will be cheaper, faster and easy to use.

To access the complete interview, click here.

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.




Market mover Predictmedix offers COVID-19 mass screening and now — a telemedicine platform

As COVID-19 global cases move towards 10 million (currently 8.26 million) one company now offers COVID-19 mass screening using a revolutionary form of Artificial Intelligence (AI). The technology also works for infection screening, sobriety testing and various other medical conditions such as mental disorders (depression & dementia). Early adopters are companies wanting to safeguard their workers as well as healthcare operations wanting to keep their premises safe from COVID-19 infection. The technology is suitable for large scale screening by governments, law enforcement, healthcare, other organizations, and employers worldwide.

That company is Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF). Predictmedix has developed a disruptive AI technology that is leading the future in impairment detection and healthcare screenings. Predictmedix‘s AI powered products use facial, thermal, video and audio recognition technologies to determine when individuals are impaired or suffering from infectious disease or mental illness.

In the case of infection, the Predictmedix technology can screen and detect early signs such as temperature variances on the face and body, eye redness, coughing, sneezing, and other signs suggesting infection.

The potential applications are enormous. Imagine the impact this can have on COVID-19 detection, by putting Predictmedix’s mass screening technology in all public places. Combine this with further specific COVID-19 testing on those individuals that are picked up on mass screening and finally we have a chance to trace and stop the coronavirus.

One example of a COVID-19 entry screening that can use Predictmedix technology

Source: Predictmedix

It is still early days for Predictmedix, however given the pace of new contracts, the Company is likely to grow exponentially. Predictmedix collect payments based on a Software as a Service (SaaS) user based model. Clients pay a monthly fee based on volume of screenings per use case, providing Predictmedix with recurring monthly revenue and multi-year contracts.

Recent contracts and partnerships with Predictmedix

  • June 19, 2020 – Acquisition of Telemedicine platform – MobileWellbeing. Predictmedix to offer a fully integrated enterprise solution for healthcare along with workplace health, safety, and compliance.
  • June 4, 2020 – Sales contract for its COVID-19 screening technology for the Caribbean region. Caribbean Digital Media Academy (CDMA) will act as a distributor for Predictmedix technology for the Caribbean with a specific focus on government and hospitality sectors.
  • June 4, 2020 – Partnership with Max Healthcare for facial technologies leading to neurological diagnostics for mental health disorders. Max Healthcare is one of the largest healthcare groups in South Asia, encompassing 14 hospitals with over 3000 doctors.
  • May 20, 2020Sales contract with Juiceworks Exhibits (events and exhibit marketing industry).
  • May 9, 2020 – Deployment of COVID-19 mass screening technology with Max Healthcare. 
  • April 22, 2020 – Launch of a Pilot with Hindalco Industries Ltd for its impairment detection AI technology.

What the experts are saying:

  • Kapil Raval (Director of Artificial Intelligence Business Development at Microsoft) – “The most interesting part is that Predictmedix focuses on AI solutions to problems that matter to all of us.”
  • Dr Navdeep Singh Nanda – “Predictmedix can make a huge impact on the current COVID19 pandemic as their technology is the need of the day not just now but also in the future as we deal with other infectious diseases.”
  • Dr Alexander Bardon (Emergency Physicia) – “There is not going to be a medical​ breakthrough such as a vaccine or drug that is going to solve the COVID19 problem in the near future. Our only effective strategy is the prevention of viral transmission. We have applied travel bans and physical distancing orders to our society as a whole. This has had a devastating impact on our economy and way of life. With AI we could be much more tactful in our approach.

Predictmedix is moving forward at an incredible pace landing several new contracts and even appointing Microsoft Director of Business Development AI Solutions, Kapil Raval, as the Chairman of their Advisory Board. What started as a technology to detect for impairment has grown to detect infection and other medical conditions. Predictmedix offers an incredibly simple, cheap, yet brilliant, way to mass test globally for COVID-19 in public places without inconveniencing people. They combine this with a simple SaaS revenue collection model.

For investors all the signs are there. Predictmedix already has brilliant technology, early adopters, new contracts, a massive near term demand for COVID-19 screening technology, and now a telemedicine platform to better connect patients and healthcare providers.

Predictmedix stock has been rising fast, but still has a market cap of only C$66 million. Don’t miss this one.